Stockscreener 앱 받기
544.33
1.12%
6.03
시간 외 거래:
544.34
0.010
+0.00%
전일 마감가:
$538.30
열려 있는:
$542.08
하루 거래량:
783.97K
Relative Volume:
1.54
시가총액:
$23.11B
수익:
$3.17B
순이익/손실:
$1.29B
주가수익비율:
20.09
EPS:
27.0947
순현금흐름:
$1.01B
1주 성능:
-0.72%
1개월 성능:
-4.24%
6개월 성능:
+6.64%
1년 성능:
+90.07%
1일 변동 폭
$539.70
$546.58
1주일 범위
$532.59
$555.92
52주 변동 폭
$272.12
$609.35
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, HLN, TEVA, ZTS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
544.33 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
15.84 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.95 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.21 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.84 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
Martine Rothblatt, United Therapeutics CEO, sells $5.1m in stock - Investing.com
Form 4 United Therapeutics Corporation For: 22 June By Investing.com - Investing.com Canada
Martine Rothblatt, United Therapeutics CEO, sells $5.1m in stock By Investing.com - Investing.com Canada
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks - StockStory
United Therapeutics EVP Mahon sells $4.5m in company stock - Investing.com UK
United Therapeutics EVP Mahon sells $4.5m in company stock By Investing.com - Investing.com South Africa
United Therapeutics StockThursday technical picture and trading levels - AD HOC NEWS
United Therapeutics Corp (UTHR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
United Therapeutics Corp (UTHR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
United Therapeutics CEO Rothblatt sells $5.2m in shares - Investing.com
United Therapeutics Corp (UTHR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
United Therapeutics' Liver Assist Product Earns FDA Regenerative Medicine Advanced Therapy Designation - Medical Product Outsourcing
United Therapeutics CFO Edgemond sells $5.49m in common stock By Investing.com - Investing.com India
United Therapeutics CFO Edgemond sells $5.49m in common stock - Investing.com
United Therapeutics Corp (UTHR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
United Therapeutics Corporation (UTHR) Stock Analysis: Exploring a 21.85% Upside Potential - DirectorsTalk Interviews
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics CFO Edgemond sells $5.49m in company stock By Investing.com - Investing.com Nigeria
United Therapeutics CFO Edgemond sells $5.49m in company stock - Investing.com
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.2m in stock By Investing.com - Investing.com South Africa
Martine Rothblatt, United Therapeutics chairperson & CEO, sells $5.2m in stock - Investing.com Nigeria
Neuroblastoma Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Y-mAbs Therapeutics, United Therapeutics Corp, EUSA Pharma, Clarity Pharma, Eli Lilly - Barchart
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns - The Motley Fool
United Therapeutics CEO Rothblatt sells $5.2m in shares By Investing.com - Investing.com South Africa
United Therapeutics CFO James Edgemond sells $5.48m in stock - Investing.com
United Therapeutics CFO James Edgemond sells $5.48m in stock By Investing.com - Investing.com South Africa
Goodwin Advises Ascidian Therapeutics On A Global Research Collaboration With Eli Lilly For Up To $1.9 Billion - Mondaq
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in stock By Investing.com - Investing.com South Africa
Martine Rothblatt, United Therapeutics CEO, sells $5.2m in stock - Investing.com
United Therapeutics Corporation (UTHR) Stock Analysis: Investor Outlook on Robust Growth Potential with 20.98% Upside - DirectorsTalk Interviews
United Therapeutics CEO Rothblatt sells $5.47m in stock - Investing.com
UTHRUnited Therapeutics Corp Stock Price and Quote - Finviz
Why Is United Therapeutics (UTHR) Down 3.8% Since Last Earnings Report? - Yahoo Finance
How The Story Around United Therapeutics (UTHR) Is Shifting On Trials Pricing And Valuation - Yahoo Finance
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
United Therapeutics EVP Mahon sells $4.54 million in stock - Investing.com UK
United Therapeutics Q1 2026 slides: IPF breakthrough offsets revenue miss - Investing.com
MannKind stock surges on United Therapeutics partnership deal - Investing.com
United Therapeutics EVP Mahon sells $4.54 million in stock By Investing.com - Investing.com Australia
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
유나이티드 테라퓨틱스 주식 (UTHR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EDGEMOND JAMES | CFO AND TREASURER |
Jun 18 '26 |
Sale |
540.15 |
10,000 |
5,401,488 |
18,876 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 18 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 18 '26 |
Sale |
540.18 |
9,500 |
5,131,711 |
40,513 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jun 18 '26 |
Option Exercise |
146.03 |
8,300 |
1,212,049 |
53,472 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jun 18 '26 |
Sale |
541.55 |
8,300 |
4,494,841 |
45,172 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 17 '26 |
Option Exercise |
146.03 |
9,500 |
1,387,285 |
50,013 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Jun 17 '26 |
Sale |
552.40 |
9,500 |
5,247,802 |
40,513 |
2.41%
0.11%
자본화:
|
볼륨(24시간):